Novel strategies towards engineering therapeutic enzymes with reduced immunogenicity for cancer therapy
Heterologous enzymes have been investigated for a variety of therapeutic applications, including the treatment of a number of cancers that are sensitive to the systemic depletion of specific amino acids. One such example is acute lymphoblastic leukemia (ALL) for which enzyme-mediated L-Asparagine (L...
Main Author: | Cantor, Jason Robert |
---|---|
Format: | Others |
Language: | English |
Published: |
2012
|
Subjects: | |
Online Access: | http://hdl.handle.net/2152/ETD-UT-2010-12-2141 |
Similar Items
-
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020
by: Vibha Jawa, et al.
Published: (2020-06-01) -
L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo
by: Saleh A. Mohamed, et al.
Published: (2016-10-01) -
Editorial: Immunogenicity of Proteins Used as Therapeutics
by: Zuben E. Sauna, et al.
Published: (2020-10-01) -
Purification, characterization and immunogenicity assessment of glutaminase free L-asparaginase from Streptomyces brollosae NEAE-115
by: Noura El-Ahmady El-Naggar, et al.
Published: (2018-08-01) -
Diverse Enzymes With Industrial Applications in Four Thraustochytrid Genera
by: Hsiu-Chin Lin, et al.
Published: (2020-10-01)